The Australian Government is ensuring thousands of Australians, with or at risk of contracting HIV, are protected by securing the supply of tenofovir with emtricitabine, or PrEP, by temporarily approving the supply on an alternative overseas-registered brand.
Pre-exposure prophylaxis (PrEP) is an anti-viral medicine taken by someone who does not have HIV to lower their chance of catching HIV.
From 1 October 2024, the Laurus Labs, USA-registered brand will be listed on the Pharmaceutical Benefits Scheme (PBS), to allow supply at a subsidised cost for the period of the shortage.
The listing means over 27,000 eligible patients will have continued access to this important medicine and pay a maximum of just $31.60 per script, or just $7.70 with a concession card.
Importantly, for Australians that use PrEP the supply situation is improving.
The government anticipates the supply of tens of thousands of units will resolve the shortage by early November, with approximately 4 months supply in the country by then, with future planned deliveries meeting normal ongoing demand.
Quotes attributable to Minister Butler:
“PrEP is highly important for Australians living with or at risk of HIV and we have taken swift action to ensure they are protected from current shortages.
“This listing will ensure Australians continue to have access to a world-class medication at an affordable price.
“We are committed to supporting those with HIV and to the once thought impossible goal of eliminating transmission of HIV in Australia by 2030.”
